Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.

Kim MM, Speers C, Li P, Schipper M, Junck L, Leung D, Orringer D, Heth J, Umemura Y, Spratt DE, Wahl DR, Cao Y, Lawrence TS, Tsien CI.

J Neurooncol. 2019 Jun;143(2):313-319. doi: 10.1007/s11060-019-03166-3. Epub 2019 Apr 11.

PMID:
30977058
2.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
3.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
4.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

5.

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.

Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH, Cho YH, Yoon SM, Chang JH, Kang SG, Kim EH, Suh CO, Jung TY, Lee KH, Kim CY, Kim IA, Hong CK, Yoo H, Kim JH, Kang SH, Kang MK, Kim EY, Kim SH, Chung DS, Hwang SC, Song JH, Cho SJ, Lee SI, Lee YS, Ahn KJ, Kim SH, Lim DH, Gwak HS, Lee SH, Hong YK.

Cancer Res Treat. 2017 Jan;49(1):193-203. doi: 10.4143/crt.2015.473. Epub 2016 Jun 27.

6.

Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?

Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, K├Ânig R, Wirtz CR, Coburger J.

Clin Neurol Neurosurg. 2018 Apr;167:6-10. doi: 10.1016/j.clineuro.2018.02.003. Epub 2018 Feb 5.

PMID:
29425743
7.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC; German Glioma Network.

Ann Oncol. 2013 Dec;24(12):3117-23. doi: 10.1093/annonc/mdt388. Epub 2013 Oct 14.

8.

The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.

Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD.

Acta Neurochir (Wien). 2016 Oct;158(10):1943-53. doi: 10.1007/s00701-016-2928-8. Epub 2016 Aug 15.

PMID:
27526690
9.

Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.

Gessler F, Bernstock JD, Braczynski A, Lescher S, Baumgarten P, Harter PN, Mittelbronn M, Wu T, Seifert V, Senft C.

Neurosurgery. 2019 Jan 1;84(1):190-197. doi: 10.1093/neuros/nyy049.

PMID:
29617848
10.

Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.

Chen L, Guerrero-Cazares H, Ye X, Ford E, McNutt T, Kleinberg L, Lim M, Chaichana K, Quinones-Hinojosa A, Redmond K.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):616-22. doi: 10.1016/j.ijrobp.2013.02.014. Epub 2013 Mar 26.

11.

Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.

Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, Linette G, Jalalizadeh R, Dacey R, Rich KM, Chicoine MR, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):877-85. doi: 10.1016/j.ijrobp.2014.07.014. Epub 2014 Sep 23.

PMID:
25257812
12.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
13.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

14.

Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Mallick S, Kunhiparambath H, Gupta S, Benson R, Sharma S, Laviraj MA, Upadhyay AD, Julka PK, Sharma D, Rath GK.

J Neurooncol. 2018 Oct;140(1):75-82. doi: 10.1007/s11060-018-2932-3. Epub 2018 Jun 23.

PMID:
29936695
15.

Clinicoradiological features and surgical outcomes of primary intracranial medulloepitheliomas: a single-center experience and pooled analysis of individual patient data.

Li D, Hao SY, Wang L, Li GL, Wang JM, Wu Z, Zhang LW, Zhang JT, Jia W.

J Neurosurg. 2018 Jul 1:1-15. doi: 10.3171/2018.1.JNS172509. [Epub ahead of print]

PMID:
29979121
16.

Surgical management and long-term outcomes of intracranial giant cell tumors: a single-institution experience with a systematic review.

Weng JC, Li D, Wang L, Wu Z, Wang JM, Li GL, Jia W, Zhang LW, Zhang JT.

J Neurosurg. 2018 Oct 1:1-11. doi: 10.3171/2018.4.JNS1849. [Epub ahead of print]

PMID:
30497189
17.

Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study.

Roh TH, Kang SG, Moon JH, Sung KS, Park HH, Kim SH, Kim EH, Hong CK, Suh CO, Chang JH.

J Neurosurg. 2019 Mar 1:1-7. doi: 10.3171/2018.12.JNS182558. [Epub ahead of print]

PMID:
30835701
18.

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.

Greer L, Pannullo SC, Smith AW, Taube S, Yondorf MZ, Parashar B, Trichter S, Nedialkova L, Sabbas A, Christos P, Wernicke AG.

Cureus. 2017 Jun 24;9(6):e1388. doi: 10.7759/cureus.1388.

19.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

20.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327

Supplemental Content

Support Center